Cyclacel Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Cyclacel Pharmaceuticals has a total shareholder equity of $607.0K and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $8.8M and $8.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$3.38m |
Equity | US$607.00k |
Total liabilities | US$8.20m |
Total assets | US$8.81m |
Recent financial health updates
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely
Aug 17Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?
Apr 15Recent updates
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely
Aug 17Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis
Aug 07Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?
Apr 15Cyclacel CEO Spiro Rombotis - Addressing Cancer Resistance (Video)
Oct 04Cyclacel issues key business objectives for 2021
Jan 11Cyclacel Pharma inks securities purchase agreement for $7M
Dec 22Cyclacel Pharmaceuticals EPS misses by $1.74
Nov 11Financial Position Analysis
Short Term Liabilities: CYCC's short term assets ($7.4M) do not cover its short term liabilities ($8.2M).
Long Term Liabilities: CYCC's short term assets ($7.4M) exceed its long term liabilities ($37.0K).
Debt to Equity History and Analysis
Debt Level: CYCC is debt free.
Reducing Debt: CYCC has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYCC has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CYCC is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.